Statement: There were no cases of Leukopenia, Epitasis or Arrhythmia observed in patients participating in the primary trial.
Primary_evidence: Adverse Events 1:   Total: 18/26 (69.23%)   Thrombocytopenia * 4/26 (15.38%)   Neutropenia * 3/26 (11.54%)   Epitasis * 1/26 (3.85%)   Peripheral arterial ischemia * 1/26 (3.85%)   Thrombosis *  [1]1/26 (3.85%)   Weakness * 1/26 (3.85%)   Pain *  [2]2/26 (7.69%)   Febrile neutropenia * 1/26 (3.85%)   Aspartate Aminotransferase *  [3]1/26 (3.85%)   Syncope * 1/26 (3.85%)